Bishkek, Kyrgyzstan, 25 February 2022 - Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received registration approval from the Kyrgyzstan Department of Medicines and Medical Devices for three of its proprietary products: the Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), Foxtrot® NC PTCA Balloon Catheter (Foxtrot® NC), and Foxtrot® Pro PTCA Coronary Balloon Catheter (Foxtrot® Pro).
Firehawk® is a drug-eluting stent (DES) with patented grooved struts and a precision targeting drug-releasing technology. Firehawk®’s hair-thin, dense CoCr alloy struts consist of nearly 600 meticulously cut grooves through which the drug is delivered, using fully automated 3D printing and groove-filling techniques. Firehawk® combines the merits of bare metal and drug-eluting stents, ensuring the same clinical efficacy but with a significantly lower drug dosage.
The Foxtrot® Pro Balloon Catheter is a rapid exchange balloon catheter designed to enlarge a patient’s lesion prior to stent implantation in percutaneous transluminal coronary angioplasty (PTCA) procedures. With excellent crossability and trackability, it offers additional solutions for more complex lesions. Its ultra-long hydrophilic coating improves its crossability and pushability, making it suitable for use in balloon-stent kissing techniques.
The Foxtrot® NC Balloon Catheter is suitable for both pre-dilation of culprit lesions prior to stent implantation and for precise post-dilation of stents after their implantation. Foxtrot® NC is a low-compliant balloon catheter and has a short deflation time. Super hydrophilic coating allows the catheter to move freely in vessels and reach the narrow lesion area smoothly, whilst two radiopaque markers aid in the positioning of the balloon under fluoroscopy during procedures. The catheter has excellent crossability, trackability and pushability.
The approval in Kyrgyzstan of these three outstanding products offered by MicroPort® fully demonstrates the company’s excellent product portfolio in the field of coronary intervention, further expanding the company’s global presence. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with higher-quality, innovative high-end medical devices and integrated solutions.
About Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians with higher-quality, innovative high-end medical devices and integrated solutions.